PL3062791T3 - Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym - Google Patents

Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym

Info

Publication number
PL3062791T3
PL3062791T3 PL14858402T PL14858402T PL3062791T3 PL 3062791 T3 PL3062791 T3 PL 3062791T3 PL 14858402 T PL14858402 T PL 14858402T PL 14858402 T PL14858402 T PL 14858402T PL 3062791 T3 PL3062791 T3 PL 3062791T3
Authority
PL
Poland
Prior art keywords
attention
neurodegenerative disorder
cognitive disorders
dementia associated
novel treatments
Prior art date
Application number
PL14858402T
Other languages
English (en)
Inventor
Sandhya Kortagere
Original Assignee
Drexel University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drexel University filed Critical Drexel University
Publication of PL3062791T3 publication Critical patent/PL3062791T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14858402T 2013-10-28 2014-10-28 Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym PL3062791T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361896173P 2013-10-28 2013-10-28
EP14858402.2A EP3062791B1 (en) 2013-10-28 2014-10-28 Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
PCT/US2014/062644 WO2015066019A1 (en) 2013-10-28 2014-10-28 Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder

Publications (1)

Publication Number Publication Date
PL3062791T3 true PL3062791T3 (pl) 2020-06-15

Family

ID=53005024

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14858402T PL3062791T3 (pl) 2013-10-28 2014-10-28 Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym

Country Status (11)

Country Link
US (4) US9861594B2 (pl)
EP (1) EP3062791B1 (pl)
JP (1) JP6607852B2 (pl)
KR (1) KR102266696B1 (pl)
CN (1) CN105848655B (pl)
AU (1) AU2014342520B2 (pl)
CA (1) CA2928429C (pl)
ES (1) ES2769780T3 (pl)
IL (1) IL245090A0 (pl)
PL (1) PL3062791T3 (pl)
WO (1) WO2015066019A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI874834B (zh) 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CR20200621A (es) 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
US11911373B2 (en) * 2018-08-16 2024-02-27 Technion Research & Development Foundation Limited Attention evaluation and methods for medicating
US20250186369A1 (en) * 2022-03-07 2025-06-12 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL57240C (pl) 1940-02-21
US5352688A (en) 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0641202A1 (en) 1992-05-18 1995-03-08 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
DE60008697T2 (de) 2000-03-28 2005-02-10 Council Of Scientific And Industrial Research Verfahren zur Herstellung von 4-(P-methoxyphenyl)-2-amino-butane und Insektizide
BRPI0411800A (pt) 2003-06-23 2006-08-08 Neurochem Int Ltd candidatos a fármacos e métodos para sua preparação
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
CA2551944A1 (en) 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
EP1851190A4 (en) 2005-01-18 2009-04-08 Univ Florida COMPOSITIONS AND METHODS FOR PAIN-RESISTANCE
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0505509D0 (en) 2005-03-17 2005-04-27 Ic Innovations Ltd Compounds
CA2613631A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
DE102005029468A1 (de) 2005-06-24 2006-12-28 Plt Patent & Licence Trading Ltd. Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms
WO2007022415A2 (en) 2005-08-18 2007-02-22 Pharmacopeia, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
JP2009537532A (ja) 2006-05-15 2009-10-29 セネックス バイオテクノロジー,インク. 腫瘍細胞増殖の選択的阻害剤としてのcdki経路阻害剤
WO2008042755A2 (en) * 2006-09-29 2008-04-10 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
JP4142073B2 (ja) * 2006-10-13 2008-08-27 株式会社コナミデジタルエンタテインメント 表示装置、表示方法、ならびに、プログラム
CL2007003130A1 (es) 2006-10-30 2008-05-30 Boehringer Ingelheim Int Uso de una formulacion de liberacion inmediata con un ingrediente activo seleccionado de pramipexol, hidrocloruro de pramipexol, dihidrocloruro de pramipexol monohidrato o una sal farmaceuticamente aceptable de este, para el tratamiento de la enferme
WO2008107335A1 (en) 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Aminoamides as orexin antagonists
WO2008113364A2 (en) 2007-03-20 2008-09-25 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
MY156662A (en) 2007-11-01 2016-03-15 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
AU2009246572A1 (en) 2008-05-16 2009-11-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
ES2545795T3 (es) * 2009-04-09 2015-09-15 Cognition Therapeutics, Inc. Inhibidores del deterioro cognitivo
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
JP6245983B2 (ja) 2010-08-11 2017-12-13 ドレクセル ユニバーシティ パーキンソン病におけるジスキネジアを治療するための新規d3ドーパミン受容体アゴニスト
DE102011015842A1 (de) 2011-03-30 2012-11-08 Olaf Lichtenberger Fluorphenyl- und Fluormethoxyphenylalkylamine und deren Anwendung
TW201305624A (zh) * 2011-07-27 2013-02-01 Hon Hai Prec Ind Co Ltd 導光板修復方法
EP2747768A4 (en) * 2011-08-25 2015-10-21 Cognition Therapeutics Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES

Also Published As

Publication number Publication date
HK1225973A1 (zh) 2017-09-22
US9861594B2 (en) 2018-01-09
KR102266696B1 (ko) 2021-06-21
ES2769780T3 (es) 2020-06-29
IL245090A0 (en) 2016-06-30
AU2014342520B2 (en) 2019-08-08
US20180092865A1 (en) 2018-04-05
CN105848655B (zh) 2019-11-08
CN105848655A (zh) 2016-08-10
EP3062791A4 (en) 2017-08-16
US20240074993A1 (en) 2024-03-07
CA2928429A1 (en) 2015-05-07
US11744810B2 (en) 2023-09-05
CA2928429C (en) 2022-08-30
KR20160067193A (ko) 2016-06-13
JP2016540737A (ja) 2016-12-28
WO2015066019A1 (en) 2015-05-07
US10695302B2 (en) 2020-06-30
AU2014342520A1 (en) 2016-05-05
JP6607852B2 (ja) 2019-11-20
EP3062791B1 (en) 2020-01-08
US20160256417A1 (en) 2016-09-08
EP3062791A1 (en) 2016-09-07
US20200397721A1 (en) 2020-12-24
NZ718978A (en) 2021-08-27

Similar Documents

Publication Publication Date Title
ZA201509101B (en) Financial account with group authorization
IL240337A0 (en) Deviation alert
EP3046470A4 (en) Diagnosing and treating movement disorders
GB201312279D0 (en) Neurodegenerative disorders
IL237742A0 (en) Laquinimod and pridofidine for the treatment of neurodegenerative diseases
GB201415523D0 (en) Vehicle with a deflection device, and deflection device
GB201305407D0 (en) Media Distribution
PL2956071T3 (pl) Zestaw do blokady nerwów obwodowych
GB201300538D0 (en) Polycarbonates
EP3026153A4 (en) Thread production device, and aggregating part
PT2986525T (pt) Tampa com evidência de violaçâo
SG11201506356WA (en) Dehydration-hydrolysis processes and catalysts therefor
IL245090A0 (en) New treatments for attention disorders, cognitive disorders and dementia related to a neurodegenerative disorder
PL2823971T3 (pl) Osłona obręczy koła oraz koło z taką osłoną
PL3901164T3 (pl) Zaburzenia związane z glutenem
IL276431A (en) Treatment of the brain disorders and related symptoms
SG11201509429UA (en) Process for producing phenol and/or cyclohexanone
PL3383851T3 (pl) Pochodne dekstrorfanu o stłumionej nerwowej aktywności ośrodkowej
GB2512235B (en) Security apparatus with blocking element
GB201420624D0 (en) Security Lable
SG11201509522UA (en) Process for producing phenol and/or cyclohexanone
SG11201603200VA (en) Process for making phenol and/or cyclohexanone
EP2909429A4 (en) INTERVAL CONTROL VALVE WITH DIFFERENT RADIAL INTERIORS
GB201413912D0 (en) Circular foal feeder
TWM476059U (en) Hub